Regeneron, AZ team up on drugs for obesity “superpower” geneAstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at Share XRegeneron, AZ team up on drugs for obesity “superpower” genehttps://pharmaphorum.com/news/regeneron-az-team-up-on-drugs-for-obesity-superpower-gene/
FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s WegovyNovo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which Share XFDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovyhttps://pharmaphorum.com/news/fda-ends-obesity-drug-drought/
Novo Nordisk’s semaglutide effective against obesity in new trialNovo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, Share XNovo Nordisk’s semaglutide effective against obesity in new trialhttps://pharmaphorum.com/news/novo-nordisks-semaglutide-effective-obesity-new-trial/
Price cut leads NICE to back Novo Nordisk’s obesity drug SaxendaNovo Nordisk’s Saxenda has been recommended by NICE as a treatment for obesity, ending a 10-year drought in Share XPrice cut leads NICE to back Novo Nordisk’s obesity drug Saxendahttps://pharmaphorum.com/news/price-cut-leads-nice-to-back-novo-nordisks-obesity-drug-saxenda/
Merck & Co to repurpose failed obesity drug for NASHMerck & Co is to pay $10 million to Hanmi to repurpose an obesity drug discarded by Johnson Share XMerck & Co to repurpose failed obesity drug for NASHhttps://pharmaphorum.com/news/merck-co-to-repurpose-failed-obesity-drug-for-nash/
Could GLP-1 drugs treat space headaches? NASA wants to know.Experts from NASA are keeping a close eye on UK research that tests whether drugs commonly used in Share XCould GLP-1 drugs treat space headaches? NASA wants to know.https://pharmaphorum.com/news/nasa-looks-on-as-uk-researchers-test-glp-1-drugs-against-space-headaches/
Rhythm doesn’t miss a beat as obesity drug clears phase 3 testRhythm Pharma says it has reported positive results for its obesity drug setmelanotide in two phase 3 trials, Share XRhythm doesn’t miss a beat as obesity drug clears phase 3 testhttps://pharmaphorum.com/news/rhythm-doesnt-miss-a-beat-as-obesity-drug-clears-phase-3-test/
Boehringer adds to obesity alliance with Denmark’s GubraTwo years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a Share XBoehringer adds to obesity alliance with Denmark’s Gubrahttps://pharmaphorum.com/news/boehringer-obesity-denmarks-gubra/
FDA approves PureTech’s obesity device PlenityThe FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting Share XFDA approves PureTech’s obesity device Plenityhttps://pharmaphorum.com/news/fda-approves-puretech-obesity-plenity/
